New imaging agent could revolutionize pancreatic cancer treatment planning
NCT ID NCT03851237
First seen Jan 06, 2026 · Last updated Jun 14, 2026 · Updated 15 times
Summary
This study tested a new imaging agent (64Cu-DOTA-ECL1i) for PET scans to detect a specific marker (CCR2) on pancreatic cancer cells. The goal was to see if the scan could help doctors choose the right treatment and monitor how well it works. 69 adults with pancreatic cancer participated. The approach aims to avoid ineffective therapies and their side effects by better matching patients to treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.